Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652272 · ClinicalTrials.gov registry record · NA
Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 301
- Enrollment target
NCT03652272: Completed NA study, sponsored by Northwestern University.
NCT03652272 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 301 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03652272, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 301 participants
- Enrollment target
Study Summary
There is a well-documented need for effective interventions that can help patients understand and safely adhere to prescribed medications, particularly those with greater potential for harm if not taken correctly. The investigators will leverage health and consumer technologies with their EHR-based Medication Complete Communication (EMC2) Strategy to: 1) inform patients about medication risks and safe use, 2) promote provider education and counseling about prescribed drugs and 3) monitor patient adherence outside of visits. The EMC2 Strategy could be feasible, sustainable, and readily available to ambulatory care practices.
Primary Outcome
Patients are asked about their medication's 1) indication, 2) risks or warnings (knowledge of risk/warnings, correct or incorrect per item) and 3) side effects (knowledge of at least two side effects, correct or incorrect per item). Correct answers were graded blindly by 2 reviewers and any discordance was resolved by a third pharmacist. Total scores ranged from 0-100, with a higher value associated with a better outcome, that reflects the percent correct of possible points.
Interventions
- BEHAVIORAL EMC2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2021-09-27 |
| Phase | NA |
What the finished NCT03652272 record still lists
NCT03652272 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which EMC2 is the first listed.
NCT03652272 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03652272 about?
NCT03652272 is a clinical study titled "Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy". There is a well-documented need for effective interventions that can help patients understand and safely adhere to prescribed medications, particularly those with greater potential for harm if not taken correctly. The investigators will leverage health and consumer technologies with their EHR-based ...
What is the current status of trial NCT03652272?
This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2019-02-08. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03652272?
The interventions under investigation include: EMC2 (BEHAVIORAL).
Who is sponsoring clinical trial NCT03652272?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03652272's enrollment target sits among peer trials
301 330th of 2000 higher than 1,671 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI